This study is exploring MDMA-assisted therapy for women who have both Post-Traumatic Stress Disorder (PTSD) and Opioid Use Disorder (OUD) after childbirth. Participants will receive MDMA (a drug sometimes called ecstasy) during therapy sessions. The study aims to see if this treatment can help improve PTSD symptoms. To join, you must be at least 18 years old, be a woman, and be currently taking daily methadone (180 mg or less) or buprenorphine (24 mg or less) for OUD. This is a small study, planning to enroll 15 participants, and will measure PTSD symptoms four weeks after the final therapy session.

Study design

This is an open-label study, meaning both you and the researchers will know what treatment you are receiving. It plans to enroll 15 women.

What's involved

The intervention involves three experimental sessions with MDMA-assisted therapy. The first session uses an initial dose of 100 mg MDMA HCL with a supplemental dose of 40 mg MDMA HCL.

Compensation

Not stated in the trial record.

Follow-up

Your PTSD symptoms will be measured four weeks after your third experimental therapy session.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.